Glucagon Receptor Antagonist II

A cell-permeable triarylpyrrole compound that acts as a selective, non-competitive, high affinity glucagon receptor antagonist (IC₅₀ = 3.7 nM, 63 nM, and 60 nM for inhibition of labeled glucagon binding to human, murine, and canine glucagon receptor, respectively). Exhibits diminished antagonistic properties in the presence of Mg²⁺ (by ≥ 20-fold) and exhibits poor affinity for the rat, guinea pig, and rabbit glucagon receptors (IC₅₀ >1 µM). Does not inhibit binding of glucagon-like peptide-1 (GLP-1) to the homologous GLP-1 receptor even at concentrations as high as 10 µM. Does not affect ligand binding of a panel of other GPCRs and only weakly affects p38 kinase activity (IC₅₀ = 1.44 µM). Potently inhibits glucagon-induced GTP_γS binding to G_αs (IC₅₀ = 158 nM) and adenylate cyclase activation in hGLUR-CHO cells (K_b = 25 nM). Shown to be orally bioavailable in both mice and rats.

Cell permeable: yes

Primary Target
Glucagon Receptor

Product does not compete with ATP.

Reversible: no

Target IC₅₀: 3.7 nM, 63 nM, and 60 nM for inhibition of labeled glucagon binding to human, murine, and canine glucagon receptor, respectively

Packaged under inert gas

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Dallas-Yang, Q., et al. 2002. Anal. Biochem.301, 156.
Cascieri, M.A., et al. 1999. J. Biol. Chem.274, 8694.
de Laszlo, S.E., et al. 1999. Bioorg. Med. Chem. Lett.9, 641.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Standard Handling (A)